Liminatus Pharma, Inc. Class A Common Stock
Symbol: LIMN (NASDAQ)
2.04
▼ (-16.73%) -0.410
Company Description:
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.
Key Stats
- Today's Open: $2.41
- Today's High: $2.51
- Today's Low: $2.005
- Today's Volume: 1.62M
- Yesterday Close: $2.45
- Yesterday High: $2.52
- Yesterday Low: $2.35
- Yesterday Volume: 1.80M
- Last Min Volume: 98
- Last Min High: $2.04
- Last Min Low: $2.04
- Last Min VWAP: $2.04
Company Profile
- Name: Liminatus Pharma, Inc. Class A Common Stock
- Website:
- Listed Date: 2025-05-01
- Location: LA PALMA, CA
- Market Status: Active
- CIK Number: 0001971387
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $62.52M
- Round Lot: 100
- Outstanding Shares: 27.06M
- Asset Type: CS
RECENT FILINGS FOR LIMN
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-25 | 8-K | View |
| 2025-08-15 | 3 | View |
| 2025-08-15 | NT 10-Q | View |
| 2025-08-14 | 8-K | View |
| 2025-08-13 | 424B3 | View |
| 2025-08-12 | EFFECT | View |
| 2025-07-28 | S-1/A | View |
| 2025-07-23 | 3 | View |
| 2025-07-21 | 3 | View |
| 2025-07-17 | 8-K | View |
| 2025-07-11 | 8-K | View |
| 2025-07-03 | 8-K | View |
| 2025-06-27 | SCHEDULE 13G | View |
| 2025-06-27 | 3 | View |
| 2025-06-26 | SCHEDULE 13G | View |
| 2025-06-26 | SCHEDULE 13G | View |
| 2025-06-26 | SCHEDULE 13G | View |
| 2025-06-24 | S-1 | View |
| 2025-06-24 | 8-K | View |
| 2025-06-24 | 8-K | View |
Latest News on LIMN